Related Experiment Videos
Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results.
Claire Daban1, Anabel Martínez-Arán, Carla Torrent
1Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, Spain.
Journal of Clinical Psychopharmacology
|April 25, 2006
Summary
Lamotrigine (LTG) may offer a safer neurocognitive profile for bipolar disorder patients compared to other anticonvulsants. This study found LTG users performed better on verbal fluency and potentially immediate verbal memory tasks.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Bipolar disorder significantly impacts cognitive function.
- Lamotrigine (LTG) is increasingly used for bipolar disorder, but its cognitive effects are understudied.
- Existing anticonvulsants like carbamazepine and valproate may have variable cognitive impacts.
Purpose of the Study:
- To evaluate the neurocognitive effects of lamotrigine (LTG) in patients with bipolar disorder.
- To compare cognitive performance in patients treated with LTG versus other anticonvulsants (carbamazepine or valproate).
Main Methods:
- Cognitive assessment of 33 bipolar I and II patients.
- Comparison of patients receiving LTG (n=15) versus carbamazepine or valproate (n=18).
- Evaluation of verbal memory, attention, and executive functions.
Main Results:
- Patients on LTG showed better performance on the verbal fluency task compared to those on other anticonvulsants.
- A moderate effect size indicated potential differences in immediate verbal memory (California Verbal Learning Test) between groups.
- LTG group patients were more likely diagnosed with bipolar II disorder and had fewer hospitalizations.
Conclusions:
- Lamotrigine (LTG) may possess a safer neurocognitive profile in bipolar disorder patients compared to carbamazepine or valproate.
- Further research is warranted to confirm these preliminary findings on LTG's cognitive impact.